<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34981437</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-2443</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurovirology</Title><ISOAbbreviation>J Neurovirol</ISOAbbreviation></Journal><ArticleTitle>Compassionate-use pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis.</ArticleTitle><Pagination><StartPage>329</StartPage><EndPage>334</EndPage><MedlinePgn>329-334</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13365-021-01038-z</ELocationID><Abstract><AbstractText>A 71-year-old woman previously on rituximab treatment for rheumatoid arthritis presented with 2 years of progressive neurologic symptoms. She was found to have persistent hypogammaglobulinemia and B cell depletion despite rituximab discontinuation a year prior. MRI revealed diffuse meningeal enhancement along the entire neuroaxis. LP showed a CSF lymphocytic pleocytosis, elevated protein, and presence of enterovirus by PCR. The patient was hospitalized several times for progressive clinical and radiologic decline, though she had transient improvements following treatment with immunoglobulin therapy. Her CSF remained positive for enterovirus PCR for at least 12 months. Though two brain biopsies were non-diagnostic, pan-Enterovirus was ultimately identified using a high-throughput next-generation sequencing technique. She was treated with compassionate-use pocapavir with clinical stabilization at 4-month follow-up; however, she expired 8 months later from a bacterial pneumonia.</AbstractText><CopyrightInformation>&#xa9; 2022. Journal of NeuroVirology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1158-5430</Identifier><AffiliationInfo><Affiliation>Department of Neurology, New York Presbyterian - Columbia University Irving Medical Center, New York, NY, 10032, USA. see2132@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakkar</LastName><ForeName>Riddhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Kathryn T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Swedish Neuroscience Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bearden</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Child Neurology, University of Rochester, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Nischay</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakur</LastName><ForeName>Kiran T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York Presbyterian - Columbia University Irving Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>Claire S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-2133-9607</Identifier><AffiliationInfo><Affiliation>Department of Neurology, New York Presbyterian - Columbia University Irving Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurovirol</MedlineTA><NlmUniqueID>9508123</NlmUniqueID><ISSNLinking>1355-0284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010647">Phenyl Ethers</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4ILA3VOV97</RegistryNumber><NameOfSubstance UI="C000619933">pocapavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="Y">Meningoencephalitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010647" MajorTopicYN="N">Phenyl Ethers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral therapy</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Meningoencephalitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34981437</ArticleId><ArticleId IdType="doi">10.1007/s13365-021-01038-z</ArticleId><ArticleId IdType="pii">10.1007/s13365-021-01038-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bauer L, Manganaro R, Zonsics B et al (2019) Fluoxetine inhibits enterovirus replication by targeting the viral 2C protein in a stereospecific manner. ACS Infect Dis 5:1609&#x2013;1623</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE (2016) Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract 4:1059&#x2013;1065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2015.12.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese T, Kapoor A, Mishra N et al (2015) Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis. mBio 6:e01491-01415</Citation></Reference><Reference><Citation>Buontempo PJ, Cox S, Wright-Minogue J et al (1997) SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother 41:1220&#x2013;1225</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.41.6.1220</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett MS, Hincks JR, Benschop K et al (2016) Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J Infect Dis 215:335&#x2013;343</Citation><ArticleIdList><ArticleId IdType="pmc">5393058</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A, Ekins S, Schmidtke M, Makarov V (2019) Back to the future: advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur J Med Chem 178:606&#x2013;622</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Gofshteyn J, C&#xe1;rdenas AM, Bearden D (2016) Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol 64:94&#x2013;98</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2016.06.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday E, Winkelstein J, Webster AD (2003) Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect 46:1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jinf.2002.1066</ArticleId></ArticleIdList></Reference><Reference><Citation>Misbah SA, Spickett GP, Ryba PC et al (1992) Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol 12:266&#x2013;270</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00918150</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartier P, Debr&#xe9; M, De Blic J et al (1999) Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134:589&#x2013;596</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(99)70246-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart HA, Webster AD (2001) Treatment of potentially life-threatening enterovirus infections with pleconaril. Clinical Infectious Diseases 32:228&#x2013;235</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sham L, Bitnun A, Branson H et al (2019) Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine. Neurology 92:916&#x2013;918</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007468</ArticleId></ArticleIdList></Reference><Reference><Citation>Thivierge B (1982) Delage G [Infections of the central nervous system caused by enterovirus: 223 cases seen at a pediatric hospital between 1973 and 1981]. Can Med Assoc J 127:1097&#x2013;1102</Citation><ArticleIdList><ArticleId IdType="pubmed">6291736</ArticleId><ArticleId IdType="pmc">1862050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilfert CM, Buckley RH, Mohanakumar T et al (1977) Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med 296:1485&#x2013;1489</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197706302962601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P (2012) Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother 56:4838&#x2013;4844</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00983-12</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>